Staging of gastroenteropancreatic neuroendocrine tumors: How we do it based on an evidence-based approach

Clinical Imaging

Volumn 37, Issue 2, 2013, Pages 194-200

  McDermott, Shaunagh ^a   O'Neill, Ailbhe C ^a   Skehan, Stephen J ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Computed tomography; Magnetic resonance imaging; Neuroendocrine tumor; Positron emission tomography; Somatostatin receptor scintigraphy

Indexed keywords

COMPUTED TOMOGRAPHY; EVIDENCE-BASED; MALIGNANT TUMORS; NEUROENDOCRINE TUMORS; SOMATOSTATIN RECEPTORS;

COMPUTERIZED TOMOGRAPHY; MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PATIENT TREATMENT; POSITRON EMISSION TOMOGRAPHY; RADIOLOGY; TUMORS;

DIAGNOSIS;

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GADOXETIC ACID; MANGAFODIPIR; PENTETREOTIDE IN 111;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; EVIDENCE BASED PRACTICE; EXTRAHEPATIC METASTASIS; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; STEREOTACTIC RADIOSURGERY;

DIAGNOSTIC IMAGING; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84875237407     PISSN: 08997071     EISSN: 18734499     Source Type: Journal    
DOI: 10.1016/j.clinimag.2012.05.006     Document Type: Review

References (41)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008, 26(18):3063-3072.
2. Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst 2008, 100(18):1282-1289.
3. Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, Oberg K Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997, 8(7):685-690.
4. Bergestuen DS, Aabakken L, Holm K, Vatn M, Thiis-Evensen E Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand J Gastroenterol 2009, 44(9):1084-1091.
5. Soreide JA, van Heerden JA, Thompson GB, Schleck C, Ilstrup DM, Churchward M Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 2000, 24(11):1431-1436. 10.1007/s002680010236 [pii].
6. Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B, Kidd M A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology 2010, 92(3):143-157. 10.1159/000319784.
7. Scarpa M, Prando D, Pozza A, Esposti ED, Castoro C, Angriman I A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors. J Surg Oncol 2010, 102(7):877-888. 10.1002/jso.21708.
8. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010, 39(6):799-800.
9. Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB, Pommier RF The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 2010, 39(6):767-774.
10. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, Nutting C, Bushnell DL, Caplin ME, Yao JC The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010, 39(6):753-766.
11. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, Coppola D, Go VL NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 2010, 39(6):713-734.
12. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plockinger U ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009, 90(2):184-189.
13. Sundin A, Vullierme MP, Kaltsas G, Plockinger U ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009, 90(2):167-183.
14. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, Arnold R, Denecke T, Plockinger U, Salazar R, Grossman A ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas. Neuroendocrinology 2012, 95(2):135-156. 10.1159/000335629.
15. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, Anlauf M, Wiedenmann B, Salazar R ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012, 95(2):157-176. 10.1159/000335597.
16. Oberg K, Akerstrom G, Rindi G, Jelic S Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v223-v227.
17. The Centre for Evidence-Based Medicine, Oxford university (England). URL: http://cebm.net/levels of evidence.asp#levels.
18. Dodd JD Evidence-based practice in radiology: steps 3 and 4-appraise and apply diagnostic radiology literature. Radiology 2007, 242(2):342-354.
19. Dodd JD, MacEneaney PM, Malone DE Evidence-based radiology: how to quickly assess the validity and strength of publications in the diagnostic radiology literature. Eur Radiol 2004, 14(5):915-922.
20. Elias D, Lefevre JH, Duvillard P, Goere D, Dromain C, Dumont F, Baudin E Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think. Ann Surg 2010, 251(2):307-310.
21. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R, Baudin E Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005, 23(1):70-78.
22. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res 2006, 11(2):58-65.
23. Dromain C, de Baere T, Baudin E, Galline J, Ducreux M, Boige V, Duvillard P, Laplanche A, Caillet H, Lasser P, Schlumberger M, Sigal R MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 2003, 180(1):121-128.
24. Rockall AG, Planche K, Power N, Nowosinska E, Monson JP, Grossman AB, Reznek RH Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI. Neuroendocrinology 2009, 89(3):288-295.
25. Rummeny EJ, Marchal G Liver imaging. Clinical applications and future perspectives. Acta Radiol 1997, 38(4 Pt 2):626-630.
26. Rummeny EJ, Torres CG, Kurdziel JC, Nilsen G, Op de Beeck B, Lundby B MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies. Acta Radiol 1997, 38(4 Pt 2):638-642.
27. Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging 2004, 29(6):696-702.
28. Murphy-Lavallee J, Jang HJ, Kim TK, Burns PN, Wilson SR Are metastases really hypovascular in the arterial phase? the perspective based on contrast-enhanced ultrasonography. J Ultrasound Med 2007, 26(11):1545-1556.
29. Ringe KI, Husarik DB, Sirlin CB, Merkle EM Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010, 195(1):13-28.
30. Cruite I, Schroeder M, Merkle EM, Sirlin CB Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010, 195(1):29-41.
31. Chung WS, Kim MJ, Chung YE, Kim YE, Park MS, Choi JY, Kim KW Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging 2011, 34(2):345-353.
32. Soyer P, Boudiaf M, Place V, Sirol M, Pautrat K, Vignaud A, Staub F, Tiah D, Hamzi L, Duchat F, Fargeaudou Y, Pocard M Preoperative detection of hepatic metastases: comparison of diffusion-weighted, T2-weighted fast spin echo and gadolinium-enhanced MR imaging using surgical and histopathologic findings as standard of reference. Eur J Radiol 2011, 80(2):245-252.
33. Kenis C, Deckers F, De Foer B, Van Mieghem F, Van Laere S, Pouillon M Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a stand alone sequence?. Eur J Radiol 2012, 81(5):1016-1023.
34. Muhi A, Ichikawa T, Motosugi U, Sou H, Nakajima H, Sano K, Sano M, Kato S, Kitamura T, Fatima Z, Fukushima K, Iino H, Mori Y, Fujii H, Araki T Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011, 34(2):326-335.
35. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007, 34(10):1617-1626.
36. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007, 48(4):508-518.
37. Nikolaou A, Thomas D, Kampanellou C, Alexandraki K, Andersson LG, Sundin A, Kaltsas G The value of 11C-5-hydroxy-tryptophan (5HTP) positron emission tomography (PET) in neuroendocrine tumour diagnosis and management: experience from one center. J Endocrinol Invest 2010, 33(11):794-799.
38. Kauhanen S, Seppanen M, Ovaska J, Minn H, Bergman J, Korsoff P, Salmela P, Saltevo J, Sane T, Valimaki M, Nuutila P The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer 2009, 16(1):255-265.
39. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010, 16(3):978-985.
40. Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, Boucher E, Raoul JL Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 2009, 50(6):858-864.
41. Zalom ML, Waxman AD, Yu R, Lee J, Ih G, Wolin EM Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide. Endocr Pract 2009, 15(6):521-527.